Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb
By Nicholas G. Miller
Shares of Janux Therapeutics rose after the company formed a collaboration and license agreement with Bristol Myers Squibb to develop a tumor-activated therapeutic for solid tumors in several human cancer types.
The stock rose 15% to $15.21 in premarket trading after closing Wednesday down 70% over the past 52 weeks.
Janux will be responsible for preclinical development up to the submission of an investigational new drug application, while Bristol Myers Squibb will be responsible for subsequent development and global commercialization. Janux will remain actively involved, supporting Bristol Myers Squibb through the first Phase 1 clinical study.
Janux may receive up to $50 million in upfront and near-term milestone payments, and is eligible to receive development, regulatory and commercial milestones up to $800 million. Janux will also receive tiered royalties on global product sales.
"This collaboration marks a significant milestone for Janux, validating the strength of our tumor-activated platforms and expanding our reach in solid tumor oncology," said Chief Executive David Campbell.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
January 22, 2026 07:48 ET (12:48 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States